Immuno-Oncology | Specialty

FDA Discloses Data on Halted Pembrolizumab Myeloma Trials

September 1st 2017

The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.

Liquid Biopsy for NSCLC: Emerging Developments

August 29th 2017

Future Directions for Liquid Biopsy in NSCLC

August 29th 2017

Liquid Biopsy and Next-Generation Sequencing

August 29th 2017

Interpretation of NSCLC Plasma Genotyping Results

August 29th 2017

Liquid Biopsy: Differences Among Technologies

August 29th 2017

Plasma Genotyping Platforms: Strengths and Limitations

August 29th 2017

Plasma Testing for NSCLC EGFR & ALK Mutations

August 29th 2017

Clinical Applications for NSCLC Liquid Biopsy

August 29th 2017

How Does Liquid Biopsy Work?

August 29th 2017

The Role for Liquid Biopsy in NSCLC

August 29th 2017

Widespread Mutation Testing for NSCLC

August 29th 2017

Genetic Testing for NSCLC

August 29th 2017

Optimizing Immunotherapy Remains a Challenge in NSCLC

August 29th 2017

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

August 28th 2017

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

August 25th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Update Offers New Insight on Atezolizumab/Bevacizumab Benefit in RCC

August 24th 2017

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Dr. Hammers on Next Steps with Immunotherapy in RCC

August 24th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).